Vyvgart Hytrulo CIDP denied as duplicate or overlapping therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for vyvgart hytrulo cidp are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Vyvgart Hytrulo for CIDP as Duplicate Therapy

Blue Cross Blue Shield may issue a duplicate-therapy denial for efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo) in chronic inflammatory demyelinating polyneuropathy when another IgG-reducing or immunomodulatory agent is already active on the patient's medication profile. Common triggers include concurrent IVIg, SCIg, or another FcRn antagonist. The plan's utilization-management system flags these combinations as potentially redundant without evaluating the individualized clinical rationale. This denial is not a finding that the medication is inappropriate — it is an administrative flag that requires clinical context to resolve.

## Why This Denial Is Appealable

CIDP is a heterogeneous, often refractory condition. The treating neurologist may have strong clinical reasons for a transitional overlap period, a combination approach, or a switch from one agent to another that requires a brief concurrent period. The FDA-approved prescribing label and the applicable professional society guidance — such as that from the American Academy of Neurology or the Peripheral Nerve Society — provide the evidentiary framework for demonstrating that the concurrent use is clinically purposeful rather than duplicative. Additionally, if the patient is transitioning from IVIg or SCIg to Vyvgart Hytrulo, a temporary overlap is often medically necessary and should be documented as such.

## Federal Appeal Framework

• Internal appeal — file within the deadline on the denial notice (commonly 180 days).
• External review (ACA §2719) — fully-insured BCBS plans must allow independent external review after a final internal denial; window is approximately four months.
• ERISA §503 — self-funded employer plans must provide a full-and-fair review with a specific written rationale.
• Expedited option — strongly consider requesting expedited review given the neurological impairment risks associated with undertreated CIDP.

## Documentation to Gather

1. CIDP diagnosis confirmation — neurology records documenting the diagnosis, disease course, and severity. 2. Current and prior treatment history — a chronological list of all immunomodulatory treatments with dates, outcomes, and reasons for changes. 3. Clinical rationale for concurrent use or transition — a detailed note from the treating neurologist explaining why both agents are present on the medication list and the clinical plan (e.g., transition protocol, refractory disease requiring combination, etc.). 4. Prescriber medical-necessity letter — addressing the duplicate-therapy denial directly and explaining the non-overlapping clinical purposes. 5. FDA prescribing label for Vyvgart Hytrulo — confirming the CIDP indication and any label guidance relevant to transitions or combinations.

## Criteria-Mapping Structure

Obtain BCBS's duplicate-therapy or coverage policy for Vyvgart Hytrulo in CIDP. For each criterion or exclusion clause, place the policy language on the left and the responsive clinical documentation on the right. Specifically address the plan's definition of "duplicate" and show — using the neurologist's attestation — that the concurrent agent either serves a different clinical purpose or is present only during a medically necessary transition period.